TY - JOUR
T1 - Development of the NIH PROMIS® Sexual Function and Satisfaction Measures in Patients with Cancer
AU - Flynn, Kathryn E.
AU - Lin, Li
AU - Cyranowski, Jill M.
AU - Reeve, Bryce B.
AU - Reese, Jennifer Barsky
AU - Jeffery, Diana D.
AU - Smith, Ashley Wilder
AU - Porter, Laura S.
AU - Dombeck, Carrie B.
AU - Bruner, Deborah Watkins
AU - Keefe, Francis J.
AU - Weinfurt, Kevin P.
N1 - Funding Information:
This work was funded by grant U01AR052186 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, with additional support from the National Cancer Institute.
PY - 2013/2
Y1 - 2013/2
N2 - Introduction. We describe the development and validation of the Patient-Reported Outcomes Measurement Information System® Sexual Function and Satisfaction (PROMIS® SexFS; National Institutes of Health) measures, version 1.0, for cancer populations. Aim. To develop a customizable self-report measure of sexual function and satisfaction as part of the U.S. National Institutes of Health PROMIS Network. Methods. Our multidisciplinary working group followed a comprehensive protocol for developing psychometrically robust patient-reported outcome measures including qualitative (scale development) and quantitative (psychometric evaluation) development. We performed an extensive literature review, conducted 16 focus groups with cancer patients and multiple discussions with clinicians, and evaluated candidate items in cognitive testing with patients. We administered items to 819 cancer patients. Items were calibrated using item-response theory and evaluated for reliability and validity. Main Outcome Measures. The PROMIS SexFS measures, version 1.0, include 81 items in 11 domains: Interest in Sexual Activity, Lubrication, Vaginal Discomfort, Erectile Function, Global Satisfaction with Sex Life, Orgasm, Anal Discomfort, Therapeutic Aids, Sexual Activities, Interfering Factors, and Screener Questions. Results. In addition to content validity (patients indicate that items cover important aspects of their experiences) and face validity (patients indicate that items measure sexual function and satisfaction), the measure shows evidence for discriminant validity (domains discriminate between groups expected to be different) and convergent validity (strong correlations between scores on PROMIS and scores on conceptually similar older measures of sexual function), as well as favorable test-retest reliability among people not expected to change (interclass correlations from two administrations of the instrument, 1 month apart). Conclusions. The PROMIS SexFS offers researchers a reliable and valid set of tools to measure self-reported sexual function and satisfaction among diverse men and women. The measures are customizable; researchers can select the relevant domains and items comprising those domains for their study.
AB - Introduction. We describe the development and validation of the Patient-Reported Outcomes Measurement Information System® Sexual Function and Satisfaction (PROMIS® SexFS; National Institutes of Health) measures, version 1.0, for cancer populations. Aim. To develop a customizable self-report measure of sexual function and satisfaction as part of the U.S. National Institutes of Health PROMIS Network. Methods. Our multidisciplinary working group followed a comprehensive protocol for developing psychometrically robust patient-reported outcome measures including qualitative (scale development) and quantitative (psychometric evaluation) development. We performed an extensive literature review, conducted 16 focus groups with cancer patients and multiple discussions with clinicians, and evaluated candidate items in cognitive testing with patients. We administered items to 819 cancer patients. Items were calibrated using item-response theory and evaluated for reliability and validity. Main Outcome Measures. The PROMIS SexFS measures, version 1.0, include 81 items in 11 domains: Interest in Sexual Activity, Lubrication, Vaginal Discomfort, Erectile Function, Global Satisfaction with Sex Life, Orgasm, Anal Discomfort, Therapeutic Aids, Sexual Activities, Interfering Factors, and Screener Questions. Results. In addition to content validity (patients indicate that items cover important aspects of their experiences) and face validity (patients indicate that items measure sexual function and satisfaction), the measure shows evidence for discriminant validity (domains discriminate between groups expected to be different) and convergent validity (strong correlations between scores on PROMIS and scores on conceptually similar older measures of sexual function), as well as favorable test-retest reliability among people not expected to change (interclass correlations from two administrations of the instrument, 1 month apart). Conclusions. The PROMIS SexFS offers researchers a reliable and valid set of tools to measure self-reported sexual function and satisfaction among diverse men and women. The measures are customizable; researchers can select the relevant domains and items comprising those domains for their study.
KW - Cancer
KW - Male and female sexual dysfunction
KW - Patient-reported outcome measures
KW - Quality of life
KW - Satisfaction
KW - Sexual function
UR - http://www.scopus.com/inward/record.url?scp=84873457442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873457442&partnerID=8YFLogxK
U2 - 10.1111/j.1743-6109.2012.02995.x
DO - 10.1111/j.1743-6109.2012.02995.x
M3 - Article
C2 - 23387911
AN - SCOPUS:84873457442
SN - 1743-6095
VL - 10
SP - 43
EP - 52
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
IS - SUPPL.
ER -